Search Results for "Degludec Delayed For Novartis"
Matching Channels
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals,...
Matching News
Degludec's Japanese launch delayed as Novo holds out on pricing
Japan may have been the first country worldwide to grant a regulatory approval to Novo Nordisk's insulin degludec product Tresiba, but the once-daily basal insulin analog will not now be launched in...
FDA to discuss Novo's insulin products
FDA confirmed the Nov. 8 meeting date for the Endocrinologic and Metabolic Drugs Advisory Committee to discuss NDAs from Novo Nordisk A/S (CSE:NVO; NYSE:NVO) for insulin Degludec and insulin Degludec/...
Meeting scheduled for insulin degludec and insulin degludec/insulin aspart
Meeting scheduled to discuss the NDA for the ultra-long-acting insulin degludec & insulin degludec/insulin aspart....
Degludec Advisory Committee Is Another De Facto Delay For Novo
FDA’s advisory committee meeting on Nov. 8 falls just after the already-extended user fee date for Novo Nordisk’s long-acting insulin degludec and degludec/insulin aspart.
Novo Announces FDA Will Hold Advisory Committee On Degludec, After The Deadline
An advisory committee meeting on Nov. 8 will further delay Novo Nordisk’s long-acting insulin degludec and degludec/insulin aspart.
US FDA reviewers: Potential 'credible' CV signal with Novo Nordisk degludec meds
While US FDA drug reviewers said Novo Nordisk's insulin degludec and insulin degludec/insulin aspart were effective in treating Type I and Type II diabetes, the regulators said they identified a "po...
Degludec may allow safer insulin start in diabetics
NEW YORK (Reuters Health) - In certain insulin-naive patients with type 2 diabetes, initiating basal insulin with degludec rather than glargine may make for a smoother course.
Promising data on insulin degludec and LY2605541 at EASD meeting
New data presented yesterday at the Annual Meeting of the European Association for the Study of Diabetes (EASD), being held in Berlin, Germany, show that patients with type 2 diabetes starting insulin...
Matching PubMed Articles
Insulin degludec (Tresiba(®)) is an ultra-long-acting insulin analogue that is also available as a coformulation with rapid-acting insulin aspart (insulin degludec/insulin aspart) [Ryzodeg(®)]. Insu...
Efficacy and safety of degludec insulin: a meta-analysis of randomised trials.
Abstract Objectives: Degludec is a novel long-acting insulin analogue, providing an adequate supply of basal insulin over 24 hours with one daily injection, with a supposed greater reproducibility and...
Allosteric modulators of the calcium-sensing receptor: turning news into distinct views.
Editorial: Peer across the barrier--new live transmissions from the intestinal mucosa.
